Kingdon Capital Management, L.L.C. Bridge Bio Pharma, Inc. Transaction History
Kingdon Capital Management, L.L.C.
- $834 Million
- Q3 2024
A detailed history of Kingdon Capital Management, L.L.C. transactions in Bridge Bio Pharma, Inc. stock. As of the latest transaction made, Kingdon Capital Management, L.L.C. holds 267,500 shares of BBIO stock, worth $7.59 Million. This represents 0.44% of its overall portfolio holdings.
Number of Shares
267,500Holding current value
$7.59 Million% of portfolio
0.44%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding BBIO
# of Institutions
290Shares Held
170MCall Options Held
10.4MPut Options Held
2.37M-
Kohlberg Kravis Roberts & Co. L.P. New York, NY25.3MShares$717 Million35.94% of portfolio
-
Viking Global Investors LP25.1MShares$713 Million2.47% of portfolio
-
Vanguard Group Inc Valley Forge, PA14.2MShares$403 Million0.01% of portfolio
-
Black Rock Inc. New York, NY12.4MShares$353 Million0.01% of portfolio
-
Aisling Capital Management LP New York, NY6.07MShares$172 Million63.58% of portfolio
About BridgeBio Pharma, Inc.
- Ticker BBIO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 148,246,000
- Market Cap $4.21B
- Description
- BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabili...